Project 3 Despite overexpression of the epidermal growth factor receptor (EGFR) on nearly all head and neck squamous cell carcinomas (HNSCC), the EGFR-specific monoclonal antibody (mAb) cetuximab is effective only in a minority of patients. The modest effects of cetuximab have stimulated interest in determining its anti-tumor mechanisms and the factors that limit clinical responses, in order to improve its efficacy by combining immunotherapeutic approaches. A growing body of evidence, and our preliminary results, indicate that a tumor antigen (TA)-specific mAb, such as cetuximab, can effectively trigger TA-specific cytotoxic T lymphocyte (CTL) responses. However, these effector CTLs are not fully effective, raising the possibility that inhibitory mechanisms limit the efficacy of cetuximab in the majority of patients. Blockade of these inhibitory mechanisms could restore anti-tumor activity and enhance cetuximab efficacy. However, the inhibitory mechanism(s) that are primarily responsible for limiting cetuximab efficacy remain unknown. A high frequency of peripheral blood T-lymphocytes (PBL) and tumor infiltrating T-lymphocytes (TIL) in multiple solid tumors, including HNSCC, express elevated levels of inhibitory receptors (so-called ?checkpoints?), such as cytotoxic T lymphocyte antigen (CTLA-4) and programmed death-1 (PD-1), rendering them unresponsive to antigenic stimulation (exhaustion). Furthermore, CTLA-4+ regulatory T cells (Tregs), a potently suppressive sup- population of CD4+ T cells that produce TGF-?, are often present at increased frequencies and with enhanced suppressive capacity in tumors. Collectively, inhibitory receptors on CTL and Tregs are major barriers to effective anti-tumor T cell responses, which has been demonstrated by striking clinical responses to anti- CTLA-4 and anti-PD-1 antibodies. Our previous studies and preliminary data support a working model in which the generation of TA-specific CD8+ T cells triggered by cetuximab in the non-responder patient population occurs concurrently with increased inhibitory mechanisms (including TGF-?) that reduce the clinical response to cetuximab therapy. This project will take advantage of the availability of biospecimens from two novel UPCI clinical trials, which have either recently completed (UPCI 08-013, testing immune biomarkers in single-agent cetuximab treated patients)) or are ongoing (UPCI 12-084, combining cetuximab with anti-CTLA-4 mAb ipilimumab to inhibit Treg). We will determine whether inhibitory mechanisms are responsible for limiting anti-tumor activity induced in cetuximab-treated HNSCC patients and directly assess the impact of CTLA4+ Tregs in this new, ongoing clinical trial.

Public Health Relevance

Project 3 A new type of cancer treatment has shown success over the past decade are antibodies that target tumor cells. Unfortunately these antibodies are not fully effective in most patients, so understanding how they work and why they don?t work effectively for all patients will likely improve their success in cancer patients. We have shown that one such antibody, cetuximab, which is FDA-approved for head and neck cancer, may have limited success for patients because of inhibitory signals in the immune system. We plan to combine cetuximab with a second antibody that targets these inhibitory signals with the expectation that this approach can improve the success of cetuximab in head and neck cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097190-14
Application #
9518562
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2004-07-01
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
14
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Johnston, Paul A; Sen, Malabika; Hua, Yun et al. (2018) High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Methods Mol Biol 1683:229-244
Palliyaguru, Dushani L; Yuan, Jian-Min; Kensler, Thomas W et al. (2018) Isothiocyanates: Translating the Power of Plants to People. Mol Nutr Food Res 62:e1700965
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
Santuray, Rodell T; Johnson, Daniel E; Grandis, Jennifer R (2018) New Therapies in Head and Neck Cancer. Trends Cancer 4:385-396
Liu, Zhuqing; McMichael, Elizabeth L; Shayan, Gulidanna et al. (2018) Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res 24:4529-4538
Lu, Shanhong; Concha-Benavente, Fernando; Shayan, Gulidanna et al. (2018) STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol 78:186-193
Nikiforova, Marina N; Mercurio, Stephanie; Wald, Abigail I et al. (2018) Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 124:1682-1690
Zhong, Qian; Liu, Zhi-Hua; Lin, Zhi-Rui et al. (2018) The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res 24:659-673
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287

Showing the most recent 10 out of 310 publications